Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | FPR2 | P25090 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16463321 | 1.00 | ATM (0.54) | ATMFPR2KMT2AITGB3ITGA2B | |
| SCHEMBL17106926 | 0.95 | CYP3A4 (0.56) | ATMKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL16464284 | 0.95 | CYP3A4 (0.56) | ATMKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL7039089 | 0.85 | ATM (0.67) | ATMFPR2KMT2AITGB3ITGA2B | |
| SCHEMBL7044299 | 0.85 | ATM (0.67) | ATMFPR2KMT2AITGB3ITGA2B | |
| SCHEMBL9716778 | 0.85 | ATM (0.67) | ATMFPR2KMT2AITGB3ITGA2B | |
| SCHEMBL9716776 | 0.85 | ATM (0.67) | ATMFPR2KMT2AITGB3ITGA2B | |
| SCHEMBL7044293 | 0.85 | ATM (0.67) | ATMFPR2KMT2AITGB3ITGA2B | |
| SCHEMBL17106960 | 0.85 | CACNA1B (0.50) | ATMKMT2AITGB3ITGA2BCYP3A4 | |
| SCHEMBL16462455 | 0.85 | CACNA1B (0.50) | ATMKMT2AITGB3ITGA2BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | PSMB7, PSMB5, PSMC2 | ATM 4475/4885FPR2 3436/4885KMT2A 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.